Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
2(22%)
Results Posted
67%(2 trials)
Terminated
2(22%)

Phase Distribution

Ph not_applicable
2
22%
Ph phase_2
5
56%
Ph phase_4
1
11%
Ph phase_3
1
11%

Phase Distribution

0

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(3)
Terminated(3)
Other(1)

Detailed Status

Completed3
Terminated2
Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (55.6%)
Phase 31 (11.1%)
Phase 41 (11.1%)
N/A2 (22.2%)

Trials by Status

terminated222%
unknown111%
completed333%
withdrawn111%
active_not_recruiting222%

Recent Activity

2 active trials
Showing 5 of 9
completedphase_2

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

NCT05172999
active_not_recruitingphase_2

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
active_not_recruitingphase_2

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

NCT00788671
completednot_applicable

Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer

NCT06581679
terminatednot_applicable

Levonorgestrel-releasing Intrauterine System and Tubal Ligation

NCT04663568
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05172999Phase 2

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Completed
NCT02397083Phase 2

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Active Not Recruiting
NCT00788671Phase 2

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Active Not Recruiting
NCT06581679Not Applicable

Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer

Completed
NCT04663568Not Applicable

Levonorgestrel-releasing Intrauterine System and Tubal Ligation

Terminated
NCT05565573Phase 2

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

Unknown
NCT01943058Phase 2

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

Withdrawn
NCT01555931Phase 4

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

Completed
NCT00566644Phase 3

Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
9